ShockWave Medical - SWAV Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ShockWave Medical in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWAV shares.
View SWAV analyst ratings or view top-rated stocks.

9 equities research analysts have issued twelve-month price objectives for ShockWave Medical's shares. Their SWAV share price forecasts range from $165.00 to $310.00. On average, they anticipate the company's share price to reach $244.44 in the next twelve months. This suggests a possible upside of 29.3% from the stock's current price.
View analysts price targets for SWAV or view top-rated stocks among Wall Street analysts.

ShockWave Medical's stock was trading at $205.61 at the beginning of the year. Since then, SWAV stock has decreased by 8.1% and is now trading at $188.99.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our SWAV earnings forecast.

ShockWave Medical will be holding an earnings conference call on Thursday, February 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

ShockWave Medical, Inc. (NASDAQ:SWAV) released its quarterly earnings results on Monday, November, 8th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.12. The business had revenue of $65.16 million for the quarter, compared to analysts' expectations of $61.21 million. ShockWave Medical had a trailing twelve-month return on equity of 30.08% and a net margin of 20.48%. The company's revenue was up 232.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.38) earnings per share.

ShockWave Medical updated its earnings guidance on Wednesday, January, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $143.00 million-$144.00 million, compared to the consensus revenue estimate of $141.50 million.

8 employees have rated ShockWave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other ShockWave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

(SWAV) raised $75 million in an IPO on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

ShockWave Medical trades on the NASDAQ under the ticker symbol "SWAV."

ShockWave Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (0.96%), Allspring Global Investments Holdings LLC (0.90%), New York State Common Retirement Fund (0.60%), Strs Ohio (0.24%), Fisher Asset Management LLC (0.22%) and TD Asset Management Inc (0.14%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sofinnova Capital Vii Fcpr and Trinh Phung.
View institutional ownership trends.

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SWAV stock can currently be purchased for approximately $188.99.

ShockWave Medical (NASDAQ:SWAV) has a market capitalization of $6.83 billion and generates $237.15 million in revenue each year. The company earns $-9,140,000.00 in net income (profit) each year or $2.33 on an earnings per share basis.

The company employs 657 workers across the globe.

ShockWave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The official website for the company is www.shockwavemedical.com. The company can be reached via phone at (877) 775-4846 or via email at investors@shockwavemedical.com.